Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

dc.contributor.authorChapman, Ros
dc.contributor.authorvan Diepen, Michiel
dc.contributor.authorDouglass, Nicola
dc.contributor.authorGalant, Shireen
dc.contributor.authorJaffer, Mohamed
dc.contributor.authorMargolin, Emmanuel
dc.contributor.authorXimba, Phindile
dc.contributor.authorHermanus, Tandile
dc.contributor.authorMoore, Penny L
dc.contributor.authorWilliamson, Anna-Lise
dc.date.accessioned2021-11-29T17:04:44Z
dc.date.available2021-11-29T17:04:44Z
dc.date.issued2021-11-05
dc.date.updated2021-11-25T16:00:05Z
dc.description.abstractThe modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equivalent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1 antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM) all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by MVAGC5.en_US
dc.identifierdoi: 10.3390/vaccines9111281
dc.identifier.apacitationChapman, R., van Diepen, M., Douglass, N., Galant, S., Jaffer, M., Margolin, E., ... Williamson, A. (2021). Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV. <i>Vaccines</i>, 9(11), 1281. http://hdl.handle.net/11427/35398en_ZA
dc.identifier.chicagocitationChapman, Ros, Michiel van Diepen, Nicola Douglass, Shireen Galant, Mohamed Jaffer, Emmanuel Margolin, Phindile Ximba, Tandile Hermanus, Penny L Moore, and Anna-Lise Williamson "Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV." <i>Vaccines</i> 9, 11. (2021): 1281. http://hdl.handle.net/11427/35398en_ZA
dc.identifier.citationChapman, R., van Diepen, M., Douglass, N., Galant, S., Jaffer, M., Margolin, E., Ximba, P. & Hermanus, T. et al. 2021. Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV. <i>Vaccines.</i> 9(11):1281. http://hdl.handle.net/11427/35398en_ZA
dc.identifier.ris TY - Journal Article AU - Chapman, Ros AU - van Diepen, Michiel AU - Douglass, Nicola AU - Galant, Shireen AU - Jaffer, Mohamed AU - Margolin, Emmanuel AU - Ximba, Phindile AU - Hermanus, Tandile AU - Moore, Penny L AU - Williamson, Anna-Lise AB - The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equivalent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1 antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM) all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by MVAGC5. DA - 2021-11-05 DB - OpenUCT DP - University of Cape Town IS - 11 J1 - Vaccines LK - https://open.uct.ac.za PY - 2021 T1 - Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV TI - Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV UR - http://hdl.handle.net/11427/35398 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/35398
dc.identifier.vancouvercitationChapman R, van Diepen M, Douglass N, Galant S, Jaffer M, Margolin E, et al. Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV. Vaccines. 2021;9(11):1281. http://hdl.handle.net/11427/35398.en_ZA
dc.publisher.departmentInstitute of Infectious Disease and Molecular Medicineen_US
dc.publisher.facultyFaculty of Health Sciencesen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.sourceVaccinesen_US
dc.source.journalissue11en_US
dc.source.journalvolume9en_US
dc.source.pagination1281en_US
dc.source.urihttps://www.mdpi.com/journal/vaccines
dc.titleAssessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIVen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
vaccines-09-01281.pdf
Size:
3.13 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Collections